08:00 , Dec 22, 2014 |  BC Week In Review  |  Company News

Teva sales and marketing update

Teva launched a generic version of amlodipine/valsartan/hydrochlorothiazide in the U.S. to treat hypertension. Novartis AG (NYSE:NVS; SIX:NOVN, Basel, Switzerland) markets the combination of the calcium channel blocker amlodipine, the angiotensin receptor blocker valsartan and the...
07:00 , Oct 1, 2012 |  BC Week In Review  |  Company News

Mylan sales and marketing update

Mylan launched a generic version of hypertension drug Diovan HCT from Novartis AG (NYSE:NVS; SIX:NOVN, Basel, Switzerland) in the U.S. Mylan, which said it launched the first generic of Diovan HCT, has 180 days of...
08:00 , Jan 4, 2010 |  BC Week In Review  |  Clinical News

Diovan valsartan regulatory update

EMEA's CHMP issued a positive opinion to expand the indication of Diovan valsartan to include the treatment of hypertension in pediatric patients ages 6-18 years. The combination angiotensin receptor blocker valsartan and diuretic hydrochlorothiazide is...
08:00 , Jan 4, 2010 |  BioCentury  |  Finance

4Q approvals

4Q approvals Company Approval Amylin Pharmaceuticals Inc. (NASDAQ:AMLN)/ Eli Lilly and Co. (NYSE:LLY) FDA approves Byetta exenatide to include monotherapy in Type II diabetes AstraZeneca plc (LSE:AZN; NYSE:AZN) FDA approves once-daily Seroquel XR quetiapine as...
07:00 , Oct 26, 2009 |  BC Week In Review  |  Clinical News

Exforge HCT regulatory update

The European Commission approved an MAA from Novartis AG for Exforge HCT amlodipine/valsartan/hydrochlorothiazide as substitution therapy to treat essential hypertension in adults whose blood pressure is adequately controlled on the combination of amlodipine, valsartin and...
07:00 , Aug 3, 2009 |  BC Week In Review  |  Clinical News

Exforge HCT regulatory update

EMEA's CHMP issued a positive opinion on an MAA from Novartis for Exforge HCT amlodipine/valsartan/hydrochlorothiazide to treat essential hypertension as substitution therapy in adults whose blood pressure is adequately controlled on the combination of amlodipine,...
07:00 , May 11, 2009 |  BC Week In Review  |  Clinical News

Exforge HCT regulatory update

FDA approved an NDA from Novartis for Exforge HCT amlodipine/valsartan/hydrochlorothiazide to treat hypertension. Exforge HCT is an oral fixed-dose combination of the calcium channel blocker amlodipine, the angiotensin receptor blocker valsartan, and the diuretic hydrochlorothiazide....
07:00 , May 4, 2009 |  BC Week In Review  |  Company News

Novartis sales and marketing update

Genentech Inc. and Novartis co-market Xolair, a recombinant humanized mAb against IgE, in the U.S., and Novartis markets it elsewhere. Lucentis, a humanized mAb fragment against VEGF-A , is marketed by Genentech Inc. in the...
07:00 , Apr 6, 2009 |  BioCentury  |  Finance

1Q approvals

1Q approvals Company Approval Amgen Inc. (NASDAQ:AMGN) EC approves Nplate romiplostim to treat chronic idiopathic thrombocytopenic purpura (ITP) in splenectomised adults who are refractory to other therapies. Nplate also approved as second-line therapy in non-splenectomised...
08:00 , Feb 2, 2009 |  BC Week In Review  |  Company News

Ipsen, Novartis sales and marketing update

The partners will co-promote Novartis' Exforge amlodipine/valsartan in France to treat hypertension. Financial terms were not disclosed. Novartis markets the combination of the calcium channel blocker amlodipine and the angiotensin receptor blocker valsartan in the...